Prognostic Impact of Persistent Measurable Residual Disease in Patients with Acute Myeloid Leukemia FLT3+ Treated with Intensive Chemotherapy Plus Midostaurin - a Retrospective Study of the Polish Adult Leukemia Group (PALG)

Background: Measurable residual disease (MRD) is detected during morphological remission after standard chemotherapy in acute myeloid leukemia (AML) patients (pts). It is a strong prognostic factor for relapse and shorter overall survival (OS). Immunophenotyping by multiparameter flow cytometry (MFC) is currently the most commonly used method in AML pts. There is still a lack of studies evaluating MRD in specific AML populations in the era of targeted therapies, including thyrosine kinase inhibitors. A retrospective study in adult pts with a newly diagnosed AML FLT3+ treated with intensive chemotherapy plus midostaurin has been performed to evaluate the prognostic impact of positive MRD (MRD+) on RFS and OS.

Objectives: To assess the prognostic impact of MRD status during the clinical course of AML FLT3+ on RFS and OS.

Patients and methods: Seventy three pts with AML FLT3 were treated in Polish hematological centers between 2018 and 2021. Bone marrow aspiration was performed after induction and consolidation treatment to assess response and MRD by MFC. MRD+ was defined as ≥ 0.1% abnormal cells within mononucleated cells by MFC with diagnostic leukemia-associated immunophenotype (LAIP) and different from normal (DfN) aberrant immunophenotype approaches.

Results: The median age of the pts was 55 (range: 18-74). Induction regimen was DA "3+7" in 50 (70%), DA-90 in 8 (11%), DAC in 11 (15%), other in 2 (4%) pts. Fifty seven (78%) pts achieved first composite complete remission (CRc=CR+CRi) after 1 or 2 courses of induction, 12 (17%) had primary refractory disease (PRD) and 2 (3%) pts died in aplasia. Median number of consolidation courses was 2 (range: 1-4).

Fifty one (89%) pts with CR1 fulfill the criteria for MRD analysis after 1 or 2 courses of induction and 34 (48%) pts after consolidations. Thirty four pts had 2 timepoints evaluation: after induction and at the end of consolidation courses.

MRD+ was reported in 35 (68%) of pts after induction (median 0.5; IQR 0.25-0.85) and in 19 (52%) of pts at the end of consolidations (median 0.64; IQR 0.22-1.99).

Analysis of 4 pts groups was performed:

Group 1.: MRD+ after induction and at the end of consolidations (persistent MRD+)(n=16; 47%);

Group 2.: MRD+ after induction with conversion to MRD- at the end of consolidations (n=6; 18%);

Group 3.: MRD- after induction with conversion to MRD+ at the end of consolidations (n=2; 6%);

Group 4.: MRD- after induction and at the end of consolidations (persistent MRD-)(n=10; 29%);

Baseline clinical characteristics were similar between 4 groups regarding age, FLT3-ITD and FLT3-TKD frequency, FLT3-ITD allelic ratio (AR), WBC, PLT, peripheral blood and bone marrow blast percentage, AML type: de novovs sAML vs tAML (p-values > 0.05).

The probability of 1- year RFS was significantly lower in pts with persistent MRD+ (group 1.) vs group 2. vs 3. vs 4. (27% vs 83% vs 50% vs 78%; p=0.034, respectively). Relapse rate after 1 year was in group 1. vs 2. vs 3. vs 4.: 73% vs 16% vs 50% vs 20% (p=0.015), respectively. The shorter OS, but insignificant, was noted in group 1. vs 2. vs 3. vs 4. (p=0.49).

A univariate analysis revealed that allo-HSCT (hazard ratio [HR] 0.345; 95% confidence interval (CI), 0.152-0.784; p=0.011) and male sex (HR, 0.433; 95% CI, 0.217-0.861; p=0.017) are predictors for longer OS. MRD- at the end of consolidations (HR, 0.211; 95% CI, 0.066-0.669; p=0.008), persistent MRD- (HR, 0.252; 95% CI, 0.070-0.909; p=0.035), allo-HSCT (HR, 0.416; 95% CI, 0.183-0.947; p=0.0368) are predictors for longer RFS. However, older age (HR, 1.049; 95% CI, 1.018-1.081; p=0.0017) and higher WBC (HR, 1.005; 95% CI, 1.002-1.008; p=0.0022) are predictors for shorter RFS.

Conclusions: We observed high rate of CR1 MRD+ AML FLT3 pts after induction (68%) and at the end of consolidations (52%). Significantly lower RFS and higher relapse rate, but not OS, were noted in pts with persistent MRD+ in comparison to pts in other MRD groups. Longer follow-up period and larger studies are necessary to confirm our preliminary findings.

Patkowska:NOVARTIS: Honoraria; AMGEN: Honoraria; Astellas Pharma: Honoraria; Angelini Pharma: Honoraria; Servier: Honoraria; KCR: Consultancy. Zaucha:Gilead: Honoraria; Novartis: Honoraria; Takeda: Honoraria; BMS: Research Funding; Abbvie: Honoraria; Roche: Honoraria; Janssen: Honoraria; Abbvie: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Consultancy. Gil:Janssen: Honoraria; Novartis: Honoraria; Pfizer: Honoraria; Celgene/BMS: Honoraria; Astellas: Honoraria; Gilead: Honoraria; Abbvie: Honoraria. Libura:Novartis: Honoraria; Servier: Honoraria. Sobas:Novartis: Honoraria; Celgene/BMS: Honoraria. Pluta:Angelini: Honoraria; Astellas: Honoraria; Celgen/BMS: Honoraria; Novartis: Honoraria; Swixx Biopharma: Honoraria, Research Funding. Wierzbowska:AbbVie: Honoraria; Astellas: Honoraria; Celgene/BMS: Honoraria; Gilead: Honoraria; Janssen: Honoraria; Swixx Biopharma: Honoraria, Research Funding; Novartis: Honoraria; Servier: Honoraria.